Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Investigation of Flare and Remission in Subjects With Atopic Dermatitis
NCT03710044 · LEO Pharma · PHASE4 · withdrawn · last registry update 2024-11-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Strategic decision” | – | Registry record, LEO Pharma |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPIA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-10-27Results posted on the registry: Zambon SpA, Liposomal Cyclosporine A + standard of care (NCT03657342)
- 2025-10-21Also stopped (terminated): Incyte Corporation, Itacitinib + Calcineurin inhibitor (NCT03320642)
- 2025-10-02Results posted on the registry: St. Jude Children's Research Hospital, Ruxolitinib + Mesna (NCT05579769)
- 2025-10-02Also stopped (terminated): St. Jude Children's Research Hospital, Ruxolitinib + Mesna (NCT05579769)
- 2025-08-27Results posted on the registry: Kyungpook National University Hospital, Mycophenolate mofetil, low dose steroid + Cyclosporin, low dose steroid (NCT01282073)
- 2025-08-26Results posted on the registry: Masonic Cancer Center, University of Minnesota, filgrastim + busulfan (NCT00357565)
- 2025-07-30Results posted on the registry: Memorial Sloan Kettering Cancer Center, Letermovir Pill (NCT04017962)
- 2025-07-24Results posted on the registry: Zambon SpA, Liposomal Cyclosporine A + Standard of Care (NCT03656926)
- 2025-07-18Also stopped (terminated): AHS Cancer Control Alberta, Treatment Arm - high dose ATG + Control Arm - standard of care (NCT03456817)
- 2025-07-17Results posted on the registry: Novartis Pharmaceuticals, eltrombopag + rabbit anti-thymocyte globulin (r-ATG) (NCT04328727)
- 2025-07-16Also stopped (withdrawn): Virginia G. Kaklamani, Cyclosporin A (NCT06246786)
- 2025-07-10Phase 3 first posted: Shanxi Bethune Hospital, Induction Therapy Regimen + Pre-Treatment Regimen (NCT07059156)
- 2025-06-29Results posted on the registry: M.D. Anderson Cancer Center, Cyclosporine + Etoposide (NCT04530487)
- 2025-06-29Also stopped (terminated): M.D. Anderson Cancer Center, Cyclosporine + Etoposide (NCT04530487)
- 2025-05-16Results posted on the registry: JHSPH Center for Clinical Trials, Adalimumab (ADA) + Conventional immunosuppression (CON) (NCT03828019)
- 2025-04-01Phase 3 first posted: The University of Hong Kong, 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion + 0.1% Cyclosporin A cationic ophthalmic emulsion (NCT06903884)
- 2025-03-25Results posted on the registry: Merck Sharp & Dohme LLC, Letermovir (NCT05763823)
- 2025-03-18Results posted on the registry: Surface Ophthalmics, Inc., SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate) + Mycophenolic Acid 0.1% (NCT04734197)
- 2025-03-14Results posted on the registry: Charite University, Berlin, Germany, Sirolimus + Azathioprine (NCT00866684)
- 2025-03-14Also stopped (terminated): Charite University, Berlin, Germany, Sirolimus + Azathioprine (NCT00866684)
- 2025-03-07Results posted on the registry: Fred Hutchinson Cancer Center, Cyclophosphamide + Cyclosporine (NCT00719888)
- 2025-02-12Phase 3 first posted: Incyte Corporation, INCA034176 + Best Available Therapy (BAT) (NCT06821542)
- 2025-02-06Results posted on the registry: Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-02-06Also stopped (terminated): Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-01-16Results posted on the registry: Sumitomo Pharma Switzerland GmbH, Cultured Thymus Tissue + Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus (NCT02274662)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision